Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes

In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.

Detalles Bibliográficos
Autores principales: D'Onofrio, Luca, Coraggio, Lucia, Zurru, Annalisa, Carlone, Angela, Mignogna, Carmen, Moretti, Chiara, Maddaloni, Ernesto, Buzzetti, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383474/
https://www.ncbi.nlm.nih.gov/pubmed/34450248
http://dx.doi.org/10.1016/j.diabres.2021.109022
_version_ 1783741745361584128
author D'Onofrio, Luca
Coraggio, Lucia
Zurru, Annalisa
Carlone, Angela
Mignogna, Carmen
Moretti, Chiara
Maddaloni, Ernesto
Buzzetti, Raffaella
author_facet D'Onofrio, Luca
Coraggio, Lucia
Zurru, Annalisa
Carlone, Angela
Mignogna, Carmen
Moretti, Chiara
Maddaloni, Ernesto
Buzzetti, Raffaella
author_sort D'Onofrio, Luca
collection PubMed
description In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.
format Online
Article
Text
id pubmed-8383474
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-83834742021-08-24 Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes D'Onofrio, Luca Coraggio, Lucia Zurru, Annalisa Carlone, Angela Mignogna, Carmen Moretti, Chiara Maddaloni, Ernesto Buzzetti, Raffaella Diabetes Res Clin Pract Brief Report In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine. Elsevier B.V. 2021-09 2021-08-24 /pmc/articles/PMC8383474/ /pubmed/34450248 http://dx.doi.org/10.1016/j.diabres.2021.109022 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Brief Report
D'Onofrio, Luca
Coraggio, Lucia
Zurru, Annalisa
Carlone, Angela
Mignogna, Carmen
Moretti, Chiara
Maddaloni, Ernesto
Buzzetti, Raffaella
Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes
title Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes
title_full Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes
title_fullStr Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes
title_full_unstemmed Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes
title_short Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes
title_sort short-term safety profile of sars-cov2 vaccination on glucose control: continuous glucose monitoring data in people with autoimmune diabetes
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383474/
https://www.ncbi.nlm.nih.gov/pubmed/34450248
http://dx.doi.org/10.1016/j.diabres.2021.109022
work_keys_str_mv AT donofrioluca shorttermsafetyprofileofsarscov2vaccinationonglucosecontrolcontinuousglucosemonitoringdatainpeoplewithautoimmunediabetes
AT coraggiolucia shorttermsafetyprofileofsarscov2vaccinationonglucosecontrolcontinuousglucosemonitoringdatainpeoplewithautoimmunediabetes
AT zurruannalisa shorttermsafetyprofileofsarscov2vaccinationonglucosecontrolcontinuousglucosemonitoringdatainpeoplewithautoimmunediabetes
AT carloneangela shorttermsafetyprofileofsarscov2vaccinationonglucosecontrolcontinuousglucosemonitoringdatainpeoplewithautoimmunediabetes
AT mignognacarmen shorttermsafetyprofileofsarscov2vaccinationonglucosecontrolcontinuousglucosemonitoringdatainpeoplewithautoimmunediabetes
AT morettichiara shorttermsafetyprofileofsarscov2vaccinationonglucosecontrolcontinuousglucosemonitoringdatainpeoplewithautoimmunediabetes
AT maddaloniernesto shorttermsafetyprofileofsarscov2vaccinationonglucosecontrolcontinuousglucosemonitoringdatainpeoplewithautoimmunediabetes
AT buzzettiraffaella shorttermsafetyprofileofsarscov2vaccinationonglucosecontrolcontinuousglucosemonitoringdatainpeoplewithautoimmunediabetes

Ejemplares similares